Mbx Biosciences, INC 8-K filings

MBX Biosciences announced its second quarter 2026 financial results, highlighting progress in its hypoparathyroidism and obesity drug development programs, with a strong cash runway into 2029.

MBX Biosciences announces the departure of CEO Kent P. Hawryluk and the appointment of Steven Hoerter as the new President and CEO, effective July 13, 2026.

MBX Biosciences announced one-year clinical data for canvuparatide in chronic hypoparathyroidism, showing sustained efficacy and safety as it prepares for a Phase 3 trial.

MBX Biosciences stockholders re-elected two Class II directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

MBX Biosciences announced positive initial Phase 1 data for MBX 4291, a potential once-monthly obesity treatment, and nominated MBX 5765 as a new amycretin prodrug candidate.

MBX Biosciences announced Q1 2026 financial results, highlighting progress in its canvuparatide and MBX 4291 pipelines, with strong cash reserves extending operational runway into 2029.

MBX Biosciences reported full-year 2025 financial results, highlighting significant pipeline advancements and a strengthened balance sheet expected to fund operations into 2029.

MBX Biosciences announces a new four-year lease for specialized lab and office space in Burlington, MA, alongside a structured CFO departure and the appointment of an experienced interim replacement.

MBX Biosciences, Inc. announced the sale of 2.25 million common shares, generating approximately $87.1 million in gross proceeds to fund clinical programs and general corporate purposes.

MBX Biosciences announced the appointment of Laurie Stelzer as an independent director and chairperson of the Audit Committee, expanding the board to eight members.

MBX Biosciences reported $373.7 million in preliminary unaudited cash, cash equivalents, and marketable securities as of December 31, 2025, expected to fund operations into 2029, alongside positive clinical updates and an expanded obesity pipeline.

MBX Biosciences announced positive Phase 2 trial results for canvuparatide, a significant cash runway into 2029, and key board appointments, alongside increased Q3 operating expenses and net loss.

MBX Biosciences, Inc. successfully closed an underwritten public offering, raising approximately $187.5 million to fund its clinical-stage programs and R&D.

MBX Biosciences announced positive topline results from its Phase 2 Avail clinical trial for once-weekly canvuparatide in chronic hypoparathyroidism, achieving its primary endpoint.

MBX Biosciences announced the dosing of the first participant in its Phase 1 clinical trial for MBX 4291, a potential once-monthly treatment for obesity.

MBX Biosciences announced its second quarter 2025 financial results and provided updates on its clinical pipeline, including key trial milestones expected in Q3 2025.

MBX Biosciences announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug for the treatment of obesity, with a Phase 1 trial expected to initiate in Q3 2025.

MBX Biosciences, Inc. has released an updated corporate presentation highlighting significant progress in its precision peptide pipeline for endocrine and metabolic diseases, including key clinical milestones anticipated in 2025 and a robust financial outlook.

MBX Biosciences, Inc. held its 2025 annual meeting of stockholders, approving the election of two Class I directors and ratifying Ernst & Young LLP as its independent auditor, while also noting the departure of Dr. Carl L. Gordon from the board.

MBX Biosciences announced its Q1 2025 financial results, highlighting progress in its clinical programs and a strong cash position.

MBX Biosciences welcomes veteran pharmaceutical executive Steve Hoerter to its Board of Directors to help guide the company's next phase of growth.

MBX Biosciences announces completion of enrollment in a Phase 2 trial, progress in other clinical programs, and a strong cash position to fund operations into mid-2027.

MBX Biosciences reports positive Phase 1 topline results for MBX 1416, a potential treatment for post-bariatric hypoglycemia, showing a favorable safety profile and supporting once-weekly dosing.

MBX Biosciences announced its third quarter 2024 financial results, highlighting progress in clinical trials and a strong cash position following its IPO and Series C financing.

MBX Biosciences has officially filed its fourth amended and restated certificate of incorporation and amended and restated bylaws, completing key steps following its initial public offering.